Possibility of inducing tumor cell senescence during therapy

Oncol Lett. 2021 Jul;22(1):496. doi: 10.3892/ol.2021.12757. Epub 2021 Apr 27.

Abstract

The treatment options for cancer include surgery, radiotherapy and chemotherapy. However, the traditional approach of high-dose chemotherapy brings tremendous toxic side effects to patients, as well as potentially causing drug resistance. Drug resistance affects cell proliferation, cell senescence and apoptosis. Cellular senescence refers to the process in which cells change from an active proliferative status to a growth-arrested status. There are multiple factors that regulate this process and cellular senescence is activated by various pathways. Senescent cells present specific characteristics, such as an increased cell volume, flattened cell body morphology, ceased cell division and the expression of β-galactosidase. Tumor senescence can be categorized into replicative senescence and premature senescence. Cellular senescence may inhibit the occurrence and development of tumors, serving as an innovative strategy for the treatment of cancer. The present review mainly focuses on senescent biomarkers, methods for the induction of cellular senescence and its possible application in the treatment of cancer.

Keywords: p53; pRb. senescent biomarker; treatment; tumor cell senescence.

Publication types

  • Review

Grants and funding

This review was supported by Yunnan Fundamental Research Projects (grant no. 202001AU070141) and Yunnan Key Laboratory of Pharmacology for Natural Products Open grant (grant no. 2019G005).